United States - English - NLM (National Library of Medicine)

sciegen pharmaceuticals inc - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa should be assessed periodically. droxidopa capsules are contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions ( 5.4)]. risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa should be assessed periodically. droxidopa is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions (5.4) ]. risk summary: there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days 7 to 17 of gestation (the p

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa capsules is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions (5.4)]. risk summary there are no available data on use of droxidopa capsules in pregnant women and risk of major birth defects or miscarriage. droxidopa capsules did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats we

United States - English - NLM (National Library of Medicine)

ajanta pharma usa inc. - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa capsules are contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions (5.4)]. risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days

United States - English - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [ see warnings and precautions (5.4)]. risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days 7-17

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [ see warnings and precautions (5.4)]. risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days 7-17

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa capsules are contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions ( 5.4)]. risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. howeve

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa capsules are contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions (5.4)] . risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [ s ee warnings and precautions (5.4)]. r isk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days 7 to 1

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - droxidopa (unii: j7a92w69l7) (droxidopa - unii:j7a92w69l7) - droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (noh) caused by primary autonomic failure (parkinson's disease [pd], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. effectiveness beyond 2 weeks of treatment has not been established. the continued effectiveness of droxidopa capsules should be assessed periodically. droxidopa capsules are contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see warnings and precautions (5.4)]. risk summary there are no available data on use of droxidopa in pregnant women and risk of major birth defects or miscarriage. droxidopa did not produce significant reproductive toxicity in pregnant female rats or rabbits or in their fetuses. however, when pregnant female rats were dosed during days